The University of Chicago Header Logo

Connection

George Perry to tau Proteins

This is a "connection" page, showing publications George Perry has written about tau Proteins.
Connection Strength

5.009
  1. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
    View in: PubMed
    Score: 0.629
  2. Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. J Alzheimers Dis. 2019; 67(2):447-467.
    View in: PubMed
    Score: 0.565
  3. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2040-2047.
    View in: PubMed
    Score: 0.561
  4. Hyperphosphorylated Tau Induces Cortical Hypoexcitability in Transgenic Mouse Models: A Meta-Analysis. J Integr Neurosci. 2025 Aug 28; 24(8):39192.
    View in: PubMed
    Score: 0.224
  5. Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's disease. J Alzheimers Dis. 2024 Dec; 102(4):1074-1083.
    View in: PubMed
    Score: 0.213
  6. Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against a-synuclein and 2N4R tau. Bioorg Med Chem. 2024 Dec 15; 116:117990.
    View in: PubMed
    Score: 0.212
  7. Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics. ACS Chem Neurosci. 2024 11 06; 15(21):3915-3931.
    View in: PubMed
    Score: 0.211
  8. Meta-Analysis in Transgenic Alzheimer's Disease Mouse Models Reveals Opposite Brain Network Effects of Amyloid-ß and Phosphorylated Tau Proteins. J Alzheimers Dis. 2024; 99(2):595-607.
    View in: PubMed
    Score: 0.200
  9. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May; 162(5):1623-7.
    View in: PubMed
    Score: 0.191
  10. Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy. J Alzheimers Dis. 2022; 87(2):529-543.
    View in: PubMed
    Score: 0.174
  11. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. J Alzheimers Dis. 2021; 79(4):1517-1531.
    View in: PubMed
    Score: 0.162
  12. Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. J Alzheimers Dis. 2019; 71(2):631-645.
    View in: PubMed
    Score: 0.141
  13. Differences in structure and function between human and murine tau. Biochim Biophys Acta Mol Basis Dis. 2019 08 01; 1865(8):2024-2030.
    View in: PubMed
    Score: 0.138
  14. Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. J Biol Chem. 2018 06 01; 293(22):8462-8472.
    View in: PubMed
    Score: 0.134
  15. Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology. J Alzheimers Dis. 2017; 55(2):749-762.
    View in: PubMed
    Score: 0.123
  16. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell. 2016 10; 15(5):914-23.
    View in: PubMed
    Score: 0.119
  17. Lester (Skip) Binder (1949-2013): in the beginning was tau. J Alzheimers Dis. 2014; 40 Suppl 1:S5.
    View in: PubMed
    Score: 0.100
  18. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
    View in: PubMed
    Score: 0.092
  19. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol. 2011 Jul; 70(7):578-87.
    View in: PubMed
    Score: 0.084
  20. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009 Mar; 10(3):1386-1406.
    View in: PubMed
    Score: 0.072
  21. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis. 2008 Aug; 14(4):377-83.
    View in: PubMed
    Score: 0.069
  22. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008 Jun; 67(6):523-31.
    View in: PubMed
    Score: 0.068
  23. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):126-30.
    View in: PubMed
    Score: 0.058
  24. Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management. Curr Neuropharmacol. 2025; 23(14):1894-1917.
    View in: PubMed
    Score: 0.054
  25. Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Res Rev. 2024 01; 93:102173.
    View in: PubMed
    Score: 0.050
  26. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
    View in: PubMed
    Score: 0.049
  27. Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. Rev Neurosci. 2022 06 27; 33(4):365-381.
    View in: PubMed
    Score: 0.043
  28. The Amyloid-ß Pathway in Alzheimer's Disease. Mol Psychiatry. 2021 10; 26(10):5481-5503.
    View in: PubMed
    Score: 0.042
  29. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020 Jul; 57:102834.
    View in: PubMed
    Score: 0.039
  30. No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. J Alzheimers Dis. 2019; 67(4):1277-1289.
    View in: PubMed
    Score: 0.035
  31. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018 04; 130:331-365.
    View in: PubMed
    Score: 0.033
  32. Chronic effects of mild neurotrauma: putting the cart before the horse? J Neuropathol Exp Neurol. 2015 Jun; 74(6):493-9.
    View in: PubMed
    Score: 0.028
  33. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
    View in: PubMed
    Score: 0.019
  34. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009 Feb; 54(2):84-8.
    View in: PubMed
    Score: 0.018
  35. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007 May; 7(5):473-85.
    View in: PubMed
    Score: 0.016
  36. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci Aging Knowledge Environ. 2006 May 03; 2006(8):pe10.
    View in: PubMed
    Score: 0.015
  37. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 2006 Jun; 111(6):503-9.
    View in: PubMed
    Score: 0.015
  38. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.